Ultragenyx Pharmaceutical (RARE) Income from Continuing Operations (2013 - 2026)
Ultragenyx Pharmaceutical's Income from Continuing Operations was -$92 million in Q2 2026, compared with -$115 million a year earlier.
Powered by 
Analysis
Ultragenyx Pharmaceutical (RARE) Income from Continuing Operations (2013 - 2026) Analysis & Trends
On a trailing twelve-month basis, Ultragenyx Pharmaceutical's Income from Continuing Operations was -$585.97 million through Jun 30, 2026; for FY2025, it was -$575 million.
- In earlier years, Income from Continuing Operations was -$569 million in FY2024, -$607 million in FY2023, -$707.42 million in FY2022 and -$454.03 million in FY2021.
- The Q2 2026 figure marks the highest quarterly Income from Continuing Operations since Q3 2021.
- Per Business Quant data, RARE's Income from Continuing Operations in the three quarters before Q2 2026 was -$185 million (Q1 2026), -$128.56 million (Q4 2025) and -$180.41 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 5.28 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 3.09 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 1.10 Bn |
| 10 | Ultragenyx Pharmaceutical | 1.48 Bn | -321.29 Mn | 180.00 Mn | -92.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -92.00 Mn |
| Mar 31, 2026 | -185.00 Mn |
| Dec 31, 2025 | -128.56 Mn |
| Sep 30, 2025 | -180.41 Mn |
| Jun 30, 2025 | -115.00 Mn |
| Mar 31, 2025 | -151.00 Mn |
| Dec 31, 2024 | -133.20 Mn |
| Sep 30, 2024 | -133.52 Mn |
| Jun 30, 2024 | -131.60 Mn |
| Mar 31, 2024 | -170.68 Mn |
| Dec 31, 2023 | -123.55 Mn |
| Sep 30, 2023 | -159.65 Mn |
| Jun 30, 2023 | -159.83 Mn |
| Mar 31, 2023 | -163.97 Mn |
| Dec 31, 2022 | -151.83 Mn |
| Sep 30, 2022 | -245.11 Mn |
| Jun 30, 2022 | -158.16 Mn |
| Mar 31, 2022 | -152.32 Mn |
| Dec 31, 2021 | -122.46 Mn |
| Sep 30, 2021 | -73.00 Mn |
API Access
Ultragenyx Pharmaceutical Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=RARE&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "RARE", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=RARE&period=max&api_key=YOUR_API_KEY");
const data = await res.json();